☆ 4.7 Meeting Abstract

A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 36, Issue 6, Pages -

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1200/JCO.2018.36.6_suppl.TPS391

Keywords

-

Categories

Oncology

Funding

  1. GSK

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.